Press ReleasesDemecan Expands And Diversifies Its Network Of International Suppliers...

Demecan Expands And Diversifies Its Network Of International Suppliers Of Cannabis

-

DEMECAN has signed major supply agreements for medicinal cannabis flowers with Little Green Pharma (Denmark), Safricanna (South Africa), and Atlas Growers (Canada).

Over the next few years, DEMECAN will be supplied exclusively with at least 6 different medical cannabis flowers from these three suppliers. Deliveries will begin this year, subject to regulatory and licensing requirements. The combined amount will be over 2.2 tons of dried cannabis flower in the first year of delivery alone.

Demecan is Germany’s leading medical cannabis company and the only independent German company to have been awarded the contract by the Federal Institute for Drugs and Medical Devices (BfArM) to grow, process and distribute medical cannabis in Germany.

In April, Demecan delivered for the first time from its domestically cultivated cannabis flowers directly to the BfArM. To guarantee the security of supply for patients in Germany, Demecan also works as a pharmaceutical wholesaler with cannabis producers worldwide and imports medical cannabis.

By expanding its supplier network, Demecan will continue to lead the way in providing patients with the highest quality medical cannabis products and at the same time diversifies its supplier network for the upcoming legalization of recreational cannabis in Germany.

This allows Demecan to further consolidate its position as the go-to company for medical cannabis and at the same time provides a possible advantage for the future recreational cannabis market in Germany.

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you